• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.66% Nasdaq Up0.88%

    Ariad Pharmaceuticals Inc. (ARIA)

    7.30 Up 0.12(1.67%) 4:00PM EDT
    ProfileGet Profile for:
    Ariad Pharmaceuticals Inc.
    26 Landsdowne Street
    Cambridge, MA 02139
    United States - Map
    Phone: 617-494-0400
    Fax: 617-494-8144
    Website: http://www.ariad.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ariad Pharmaceuticals Inc.

    Corporate Governance 
    Ariad Pharmaceuticals Inc.’s ISS Governance QuickScore as of May 1, 2016 is 6. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Timothy P. Clackson Ph.D., 51
    Chief Scientific Officer and Pres of R&D
    Dr. Daniel M. Bollag Ph.D., 55
    Sr. VP of Regulatory Affairs and Quality
    Mr. Martin J. Duvall , 54
    Chief Commercial Officer and Exec. VP
    Mr. Paris Panayiotopoulos ,
    Chief Exec. Officer, Pres and Director
    Dr. David Baltimore Ph.D., 78
    Scientific Founder and Consultant
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders